PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 6, 2026European Heart Journal0 citations

NLRP3-induced endoplasmic reticulum stress, oxidative stress, and inflammatory response in the progression of diabetic cardiomyopathy

View Full Paper
MZM Z ZhouTianjin First Center HospitalHZH F ZhangSecond Hospital of Tianjin Medical UniversityXLX LiuSecond Hospital of Tianjin Medical University

Key Result

Glibenclamide ameliorated structural and electrical remodeling, oxidative stress, and inflammatory responses in a streptozotocin-induced animal model of diabetic cardiomyopathy.

Key Points

  • This research aims to explore how NLRP3 contributes to endoplasmic reticulum stress, oxidative stress, and inflammation in diabetic cardiomyopathy.
  • Animal models divided into control, diabetic, and diabetic + glibenclamide groups.
  • Diabetes induced using streptozotocin injections.
  • Echocardiography and histological examinations analyzed myocardial changes.
  • Electrophysiological assessments measured heart function and conduction.
  • Western blot analysis evaluated protein expression related to stress and inflammation.
  • Increased heart and atrial weight ratios, and altered heart dimensions were noted in diabetic models.
  • Pathological changes included disordered cell arrangement and elevated fibrosis in diabetic hearts.
  • Higher levels of reactive oxygen species were found in diabetic models compared to controls.
  • Increased expression of stress and inflammation-related proteins was observed in diabetic hearts.
  • Glibenclamide treatment improved parameters compared to untreated diabetic models.

Study Design

Type

RCT

Randomization

randomly divided

Structured PICO

Does glibenclamide ameliorate myocardial structural and electrical remodeling in a streptozotocin-induced diabetic animal model?

P
Population
Animal model of streptozotocin-induced diabetic cardiomyopathy treated with glibenclamide for 8 weeks.
I
Intervention
Glibenclamide (1.25 mg/kg) administered for 8 weeks post-diabetes induction
C
Comparator
Diabetic animals without glibenclamide (DM group) and non-diabetic controls (CTL group)
O
Outcome
Myocardial structural and electrical remodeling (assessed via echocardiography, epicardial activation mapping, in vivo electrophysiological examination, protein blotting, enzyme immunoassay, histological examination, and fluorescence staining)surrogate

Inhibition of NLRP3 with glibenclamide ameliorates structural and electrical remodeling in diabetic cardiomyopathy by reducing endoplasmic reticulum stress, oxidative stress, and inflammation.

Abstract

Abstract Objective This study aimed to investigate the mechanisms underlying the interaction between the inflammasome nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3), endoplasmic reticulum stress (ERS), oxidative stress, and inflammatory response in promoting the progression of diabetic cardiomyopathy (DCM). Methods To evaluate the role of NLRP3 in DCM pathogenesis, animals were randomly divided into three groups: control (CTL), diabetic (DM), and diabetic + glibenclamide (GLB). The diabetic model was induced by intraperitoneal injection of streptozotocin (1.25 mg/kg), and the GLB group received glibenclamide (1.25 mg/kg) for 8 weeks post-diabetes induction. Various parameters, including life signs, echocardiography, epicardial activation mapping, in vivo electrophysiological examination, protein blotting, enzyme immunoassay, histological examination, and fluorescence staining, were analyzed to assess myocardial structural and electrical remodeling in DCM. Results In the DM group, significant increases were observed in the heart-to-body weight ratio, atrial weight ratio, left atrial diameter, and septal thickness compared to the CTL group. Pathological analysis revealed disordered myocardial cell arrangement, pronounced inflammatory cell infiltration, and elevated interstitial fibrosis in the DM group. Fluorescence staining indicated higher levels of reactive oxygen species (ROS) in the DM group. Electrophysiological studies showed reduced epicardial conduction velocity, increased absolute heterogeneity and heterogeneity index, and a higher incidence of atrial fibrillation in the DM group. Western blot analysis demonstrated upregulated expression of ERS-related proteins (e.g., calcium-dependent protein kinase II, inositol-requiring protein 1 alpha), oxidative stress-related proteins (e.g., NADPH oxidase NOX2, NOX4), and inflammation-related proteins (e.g., NLRP3, caspase-1, galectin-3, transforming growth factor-β1) in the DM group. Additionally, caspase-1 activity and serum levels of interleukin (IL)-1β and IL-18 were significantly elevated in the DM group. These pathological changes were ameliorated in the GLB group compared to the DM group. Conclusions High glucose levels induce ERS in cardiomyocytes via NLRP3 activation, promoting oxidative stress and upregulating inflammatory responses, ultimately accelerating DCM progression through both structural and electrical remodeling.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zhou et al. (2025) conducted an RCT in diabetic cardiomyopathy. Glibenclamide vs. Diabetic (DM) group was evaluated on Myocardial structural and electrical remodeling. Glibenclamide ameliorated structural and electrical remodeling, oxidative stress, and inflammatory responses in a streptozotocin-induced animal model of diabetic cardiomyopathy.

synapsesocial.com/papers/698585678f7c464f23008afehttps://doi.org/10.1093/eurheartj/ehaf784.4781
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1NLRP3 Inflammasome as a Molecular Marker in Diabetic Cardiomyopathy2017 · 220 citations
  2. 2The roles of NLRP3 inflammasome in diabetic cardiomyopathy and potential targeted therapeutics2026 · 1 citations
  3. 3Effect of NLRP3 gene knockdown on pyroptosis and ferroptosis in diabetic cardiomyopathy injury2024 · 29 citations
  4. 4Non-coding RNAs affecting NLRP3 inflammasome pathway in diabetic cardiomyopathy: a comprehensive review of potential therapeutic options2025 · 8 citations
  5. 5[Expression of NLRP1 inflammasomes in myocardial tissue of diabetic rats].2020 · 2 citations